CIK 0001651308
- Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 981209416
- Phone
- +41 616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Director sold 41,463 shares at an average $30.66 ($1,271,175)
- 4 Open-market sale Director sold 47,149 shares at an average $29.61 ($1,395,992)
- 4 Open-market sale Director sold 36,443 shares at an average $31.02 ($1,130,355)
- 4 Open-market sale Director sold 67,252 shares at an average $31.42 ($2,113,061)
- 4 Grant or award CMO, Hematology acquired 300,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Grant or award CMO, Immuno-oncology acquired 300,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award EVP and Gl. Head of Bus. Dev. acquired 475,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy 10% owner bought 9,100,000 shares
- 4 Conversion 10% owner acquired 23,646,724 shares (conversion)
- 4 Conversion CEO acquired 9,398,380 shares (conversion)
- 4 Derivatives Options or other derivatives
- 4 Open-market buy CFO & Chief Strategy Officer bought 65,000 shares at $1.85 ($120,250)
- 4 Open-market buy Chief Medical Officer bought 130,000 shares at $1.85 ($240,500)
Page 28 of 29 · 580 filings